WASHINGTON, D.C. (Dec. 20, 1999) -- Dr. Judah Folkman, who discovered the process of tumor angiogenesis, and Dr. Jurgen Drews, former president of global research and development for F. Hoffmann-La Roche Ltd., will be keynote speakers at the Biotechnology Industry Organizations' (BIO) second annual CEO & Investor Conference Feb. 15-16, 2000, in New York.
This year's conference, titled 2,000 Reasons to Invest in Biotechnology, will be held at the Waldorf Astoria. Drs. Drews and Folkman are the featured lunch speakers Tuesday, Feb. 15, and Wednesday, Feb. 16, respectively.
Dr. Folkman is director of Surgical Research Laboratories at Children's Hospital and professor of pediatric surgery and cell biology at Harvard Medical School. His discovery of how angiogenesis contributes to tumor growth has led to clinical testing of numerous drug candidates aimed at preventing the formation of blood vessels that feed cancers.
Dr. Drews is chairman of International Biomedicine Management Partners Inc., a venture investment firm. At Roche, he was responsible for the company's biotechnology research projects and alliances. Dr. Drews oversaw development of Roche Bioscience and Roche's investment in Genentech.
BIO's conference is expected to draw more than 1,200 biotech and pharmaceutical company executives and investors. More than 140 biotech company CEOs will make presentations and others will participate in roundtable discussions on a variety of industry issues.
The two-day event will include 12 investor sessions, six CEO roundtables and networking receptions. A program of the conference, including online registration forms, is posted on BIO's website (http://www.bio.org/events/2000/bio2000.html).
Registration is complimentary for credentialed press. Forthose who don't register online, contact Charles Craig at BIO (202-962-9200).
BIO represents more than 850 ccompanies, academic institutions and state biotech centers in 47 states and 26 nations. BIO members are involved in the research and development of health care, agricultural, industrial and environmental biotechnology products.